On May 29, Zai Lab rose 5.51% in regular trading, trading at 14.15 HKD/share, with trading volume of 55.27 million HKD. The rebound follows a 5.03% decline on May 28 triggered by management upheaval and weak quarterly results.

On the news front, the ASCO Annual Meeting officially opened in Chicago on May 29, providing a strong catalyst for the innovative drug sector. Chinese scholars were selected for 95 oral presentations, a historic high, while 12 Chinese innovative drug companies had 13 studies chosen as late-breaking abstracts. The conference momentum drove broad-based strength across biotech names.

Zai Lab had been under pressure after its board decided that President and COO Josh Smiley would no longer serve in his role effective May 18, with Q1 total revenue declining 6% year-over-year to USD 99.6 million and net loss reaching USD 51 million. The current rebound is closely tied to sector-wide ASCO sentiment rather than company-specific developments. Within the Biotechnology sector, Innovent Bio rose 6.55% and Akeso gained 1.18%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)